JP6130491B2 - ユーイング肉腫ファミリー腫瘍を治療するための方法及び組成物 - Google Patents

ユーイング肉腫ファミリー腫瘍を治療するための方法及び組成物 Download PDF

Info

Publication number
JP6130491B2
JP6130491B2 JP2015505921A JP2015505921A JP6130491B2 JP 6130491 B2 JP6130491 B2 JP 6130491B2 JP 2015505921 A JP2015505921 A JP 2015505921A JP 2015505921 A JP2015505921 A JP 2015505921A JP 6130491 B2 JP6130491 B2 JP 6130491B2
Authority
JP
Japan
Prior art keywords
group
ews
fli1
cancer
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015505921A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015512943A5 (2
JP2015512943A (ja
Inventor
トレッツキー、ジェフリー、エー．
ブラウン、ミルトン、ラン
トッソ、ペラー、エヌ．
ウラン、エイカット
ヤリ コン
ヤリ コン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Georgetown University
Original Assignee
Georgetown University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Georgetown University filed Critical Georgetown University
Publication of JP2015512943A publication Critical patent/JP2015512943A/ja
Publication of JP2015512943A5 publication Critical patent/JP2015512943A5/ja
Application granted granted Critical
Publication of JP6130491B2 publication Critical patent/JP6130491B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/38—Oxygen atoms in positions 2 and 3, e.g. isatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2015505921A 2012-04-12 2013-04-11 ユーイング肉腫ファミリー腫瘍を治療するための方法及び組成物 Active JP6130491B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261623349P 2012-04-12 2012-04-12
US61/623,349 2012-04-12
PCT/US2013/036234 WO2013155341A1 (en) 2012-04-12 2013-04-11 Methods and compositions for treating ewings sarcoma family of tumors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017080017A Division JP6345301B2 (ja) 2012-04-12 2017-04-13 ユーイング肉腫ファミリー腫瘍を治療するための方法及び組成物

Publications (3)

Publication Number Publication Date
JP2015512943A JP2015512943A (ja) 2015-04-30
JP2015512943A5 JP2015512943A5 (2) 2017-02-23
JP6130491B2 true JP6130491B2 (ja) 2017-05-17

Family

ID=49328171

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015505921A Active JP6130491B2 (ja) 2012-04-12 2013-04-11 ユーイング肉腫ファミリー腫瘍を治療するための方法及び組成物
JP2017080017A Active JP6345301B2 (ja) 2012-04-12 2017-04-13 ユーイング肉腫ファミリー腫瘍を治療するための方法及び組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017080017A Active JP6345301B2 (ja) 2012-04-12 2017-04-13 ユーイング肉腫ファミリー腫瘍を治療するための方法及び組成物

Country Status (12)

Country Link
US (2) US9290449B2 (2)
EP (1) EP2836481B1 (2)
JP (2) JP6130491B2 (2)
KR (1) KR102145835B1 (2)
CN (2) CN107011242B (2)
AU (2) AU2013245812B2 (2)
CA (1) CA2869513C (2)
IL (1) IL234993B (2)
IN (1) IN2014DN09228A (2)
MX (1) MX377618B (2)
NZ (2) NZ700612A (2)
WO (1) WO2013155341A1 (2)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3443750B2 (ja) 1994-06-24 2003-09-08 キョーラク株式会社 ダボ付きパネル
US8232310B2 (en) 2006-12-29 2012-07-31 Georgetown University Targeting of EWS-FLI1 as anti-tumor therapy
CN107011242B (zh) * 2012-04-12 2020-08-07 乔治城大学 用于治疗尤文肉瘤家族肿瘤的方法和组合物
AU2014340398A1 (en) * 2013-10-24 2016-06-09 Georgetown University Methods and compositions for treating cancer
CN107108580B (zh) * 2014-10-09 2020-06-30 英克特诺治疗公司 吲哚酮化合物及其用途
CN107530283A (zh) 2015-03-03 2018-01-02 奎尔波特股份有限公司 组合脂质体药物制剂
CA2977397A1 (en) 2015-03-03 2016-09-09 Cureport, Inc. Dual loaded liposomal pharmaceutical formulations
EP3795563B1 (en) * 2016-03-31 2024-07-17 Oncternal Therapeutics, Inc. Indoline analogs and uses thereof
CA3029851A1 (en) 2016-07-29 2018-02-01 Oncternal Therapeutics, Inc. Uses of indoline compounds such as tk216 for the treatment of cancer
EP3558266B1 (en) * 2016-12-21 2022-03-30 The Board of Regents of The University of Texas System Altertoxin ii as a selective inhibitor of ewing family of tumor cells
CN108186630B (zh) * 2017-12-18 2020-07-31 温州医科大学 靛红类似物在制备抗肿瘤药物中的应用
CN110870917B (zh) * 2018-09-03 2022-03-15 上海市第一人民医院 Ews或其上调剂在制备治疗糖尿病及防治糖尿病个体肿瘤发生的药物中的应用
US12076310B2 (en) * 2021-06-09 2024-09-03 University Of Rochester Compounds and methods for the treatment of acute myelogenous leukemia
CN114057626B (zh) * 2021-12-07 2023-06-30 山东第一医科大学(山东省医学科学院) 一种吲哚-2,3-二酮的衍生物和制备方法、抑制recql4特异性表达的抗肝癌药物
US20250361227A1 (en) * 2022-03-13 2025-11-27 University Of Virginia Patent Foundation Inhibitors of fli1 and erg

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU583793B2 (en) 1983-07-22 1989-05-11 Du Pont Pharmaceuticals Company Phenylquinolinecarboxylic acids and derivatives as antitumor agents
EP1135123B1 (en) 1998-12-04 2004-12-29 Neurosearch A/S Use of isatin derivatives as ion channel activating agents
CN1155572C (zh) 2001-01-19 2004-06-30 中国人民解放军军事医学科学院毒物药物研究所 吲哚类衍生物及其抗肿瘤用途
US20030157486A1 (en) 2001-06-21 2003-08-21 Graff Jonathan M. Methods to identify signal sequences
US7674778B2 (en) 2004-04-30 2010-03-09 Alnylam Pharmaceuticals Oligonucleotides comprising a conjugate group linked through a C5-modified pyrimidine
AR056317A1 (es) 2005-04-20 2007-10-03 Xenon Pharmaceuticals Inc Compuestos de oxindol y composicion farmaceutica
US20090217390A1 (en) 2005-04-29 2009-08-27 Fernando Lecanda Cordero Non-human animal sarcoma model
WO2008046083A2 (en) * 2006-10-12 2008-04-17 Xenon Pharmaceuticals Inc. Use of oxindole compounds as therapeutic agents
CA2953987A1 (en) * 2006-12-29 2008-07-10 Georgetown University Targeting of ews-fli1 as anti-tumor therapy
US8232310B2 (en) 2006-12-29 2012-07-31 Georgetown University Targeting of EWS-FLI1 as anti-tumor therapy
MX2009011281A (es) * 2007-04-20 2010-03-08 Univ New York State Res Found Benzimidazol y composiciones farmaceuticas del mismo.
US8377992B2 (en) * 2007-10-22 2013-02-19 The Wistar Institute TRBD-binding effectors and methods for using the same to modulate telomerase activity
US8710068B2 (en) 2009-01-19 2014-04-29 The Trustees Of The University Of Pennsylvania Method of treating cancer using a survivin inhibitor
WO2012078519A2 (en) 2010-12-06 2012-06-14 Numerate, Inc. 3-acylidene-2-oxoindole derivatives for inhibition of transglutaminase 2
CN107011242B (zh) * 2012-04-12 2020-08-07 乔治城大学 用于治疗尤文肉瘤家族肿瘤的方法和组合物
CN103435606A (zh) 2013-08-22 2013-12-11 中国药科大学 CDK2与GSK3β双重抑制剂及用途
AU2014340398A1 (en) 2013-10-24 2016-06-09 Georgetown University Methods and compositions for treating cancer
CN107108580B (zh) 2014-10-09 2020-06-30 英克特诺治疗公司 吲哚酮化合物及其用途

Also Published As

Publication number Publication date
HK1207368A1 (en) 2016-01-29
US9714222B2 (en) 2017-07-25
JP6345301B2 (ja) 2018-06-20
EP2836481A4 (en) 2015-11-18
CA2869513C (en) 2020-07-07
CN107011242B (zh) 2020-08-07
CN104395288B (zh) 2016-12-14
JP2017141290A (ja) 2017-08-17
CN107011242A (zh) 2017-08-04
NZ723971A (en) 2018-01-26
AU2017201507A1 (en) 2017-03-23
IN2014DN09228A (2) 2015-07-10
CA2869513A1 (en) 2013-10-17
KR20150007311A (ko) 2015-01-20
MX2014011583A (es) 2016-02-09
NZ700612A (en) 2016-09-30
AU2013245812A1 (en) 2014-11-13
AU2013245812A2 (en) 2014-11-20
JP2015512943A (ja) 2015-04-30
AU2013245812B2 (en) 2017-04-06
WO2013155341A1 (en) 2013-10-17
KR102145835B1 (ko) 2020-08-20
US20160159741A1 (en) 2016-06-09
EP2836481B1 (en) 2018-12-26
US20150051260A1 (en) 2015-02-19
CN104395288A (zh) 2015-03-04
MX377618B (es) 2025-03-07
US9290449B2 (en) 2016-03-22
IL234993B (en) 2019-02-28
AU2017201507B2 (en) 2018-10-04
EP2836481A1 (en) 2015-02-18

Similar Documents

Publication Publication Date Title
JP6345301B2 (ja) ユーイング肉腫ファミリー腫瘍を治療するための方法及び組成物
JP6389884B2 (ja) 癌を治療するための方法及び組成物
JP6795861B2 (ja) インドリノン化合物及びその使用
CN109219594B (zh) 吲哚啉类似物及其用途
HK1242313A1 (en) Methods and compositions for treating ewing's sarcoma family of tumors
HK1242313B (zh) 用於治疗尤文肉瘤家族肿瘤的方法和组合物
HK40029898A (en) Indolone compounds and uses thereof
HK1207368B (en) Compounds and compositions for treating ewings sarcoma family of tumors
HK1236930B (zh) 吲哚酮化合物及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20141225

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20141225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160330

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160330

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20161013

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161018

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20170118

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170314

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170413

R150 Certificate of patent or registration of utility model

Ref document number: 6130491

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250